Cardiovascular morbidity and mortality in the losartan intervention for end point reduction in hypertension study (LIFE): a randomised trial against atenolol☆

By B. Dahlof, B. Devereux, S. Kjeldsen. 2002

798 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/7a3807ba18513d006802545e354b83eefe95db25

Citations in the corpus

• Endothelial dysfunction in diabetes mellitus (2007, neutral): “In the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study (Dahlof et al 2002), losartan was associated with 25% less new-onset diabetes compared with atenolol.”